Drug Patents owned by Neurocrine

1. List of Ingrezza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8039627 NEUROCRINE Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto
Apr, 2031

(8 years from now)

US10065952 NEUROCRINE Valbenazine salts and polymorphs thereof
Oct, 2036

(13 years from now)

US10844058 NEUROCRINE Valbenazine salts and polymorphs thereof
Oct, 2036

(13 years from now)

US10851103 NEUROCRINE Valbenazine salts and polymorphs thereof
Oct, 2036

(13 years from now)

US10851104 NEUROCRINE Valbenazine salts and polymorphs thereof
Oct, 2036

(13 years from now)

US10919892 NEUROCRINE Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
Dec, 2036

(13 years from now)

US10906902 NEUROCRINE Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
Dec, 2036

(13 years from now)

US10906903 NEUROCRINE Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
Dec, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8357697 NEUROCRINE Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto
Nov, 2027

(4 years from now)

US10874648 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US11040029 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US10912771 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US10952997 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US10857148 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US10857137 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US10993941 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US11026939 NEUROCRINE High dosage valbenazine formulation and compositions, methods, and kits related thereto
Sep, 2038

(15 years from now)

US11311532 NEUROCRINE High dosage valbenazine formulation and compositions, methods, and kits related thereto
Sep, 2038

(15 years from now)

US11026931 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Aug, 2039

(16 years from now)

US10940141 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Aug, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 11, 2022

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

NCE-1 date: April, 2021

Market Authorisation Date: 11 April, 2017

Treatment: Treatment of tardive dyskinesia; Method of administering valbenazine while avoiding concomitant use of a strong cyp3a4 inducer; Method of treating tardive dyskinesia while avoiding concomitant use of a strong cyp3a4 inducer

Dosage: CAPSULE;ORAL

How can I launch a generic of INGREZZA before it's patent expiration?
More Information on Dosage

2. List of Ongentys drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8907099 NEUROCRINE Nitrocatechol derivatives as COMT inhibitors
May, 2027

(4 years from now)

US8168793 NEUROCRINE Nitrocatechol derivatives as COMT inhibitors
Apr, 2029

(6 years from now)

US9630955 NEUROCRINE Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor
Dec, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9550759 NEUROCRINE Nitrocatechol derivatives as COMT inhibitors
Jul, 2026

(3 years from now)

US9745290 NEUROCRINE Dosage regimen for COMT inhibitors
Oct, 2027

(4 years from now)

US8524746 NEUROCRINE Dosage regimen for COMT inhibitors
Jul, 2029

(6 years from now)

US10071085 NEUROCRINE Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
Mar, 2030

(7 years from now)

US10583130 NEUROCRINE Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof
Mar, 2030

(7 years from now)

US10357468 NEUROCRINE Medicaments for slowing Parkinson's disease
May, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 24, 2025

Drugs and Companies using OPICAPONE ingredient

NCE-1 date: April, 2024

Market Authorisation Date: 24 April, 2020

Treatment: Method of inhibiting comt in the periphery; Method of treating parkinson's disease; Method of reducing o-methylation of l-dopa; Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease

Dosage: CAPSULE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic